Eledone

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Retrieved on: 
Thursday, November 2, 2023
Principal, Standard of care, United Kingdom, Trial of the century, Incidence, Tremor, EGFR, CD40L, Kidney transplantation, Banff, Glomerular filtration rate, Maintenance, Cytomegalovirus, Society, Pharmacokinetics, OLE, Hyperglycemia, Organ transplantation, ID, ATG, Webcast, Biopsy, Annual general meeting, University, Tacrolimus, Safety, Patient, Death, Hospital, Pharmaceutical industry, MD, Medicine, Eledone

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported results from the Company’s ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023.

Key Points: 
  • ET
    IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported results from the Company’s ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation.
  • Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023.
  • There have been no cases of hyperglycemia, new onset diabetes, tremor, or cytomegalovirus infection commonly seen with tacrolimus.
  • In September, Eledon announced that the first participant had been dosed in the Company’s Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Retrieved on: 
Monday, October 23, 2023
Knowledge, FDA, MedImmune, Policy, Horizon, LAM, Liver transplantation, Drug, Acquisition, Integris Health, Lymphangioleiomyomatosis, FACS, Pfizer, Neuromyelitis optica spectrum disorder, Horizon Therapeutics, University, Therapy, Patient, Transplant, Pharmaceutical industry, Dentistry, Eledone

IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs.

Key Points: 
  • IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs.
  • “We are pleased to welcome Dr. Katz to the Eledon team,” said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer.
  • “Dr.
  • Most recently, he was Chief Medical Officer at eGenesis where he helped lead the clinical development of eGenesis’ xenotransplantation programs.

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Retrieved on: 
Monday, October 2, 2023
Duke University, Pediatrics, Duke University School of Medicine, Old Dominion University, National Institute of Diabetes and Digestive and Kidney Diseases, Research, Kidney, American Journal, Patient, Organ transplantation, Kidney transplantation, American Journal of Transplantation, Digestive, Plasma protein binding, Duke, Dentistry, Eledone

IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.
  • Dr. Kirk is internationally recognized for his work in organ transplantation, with a specialized focus on kidney transplants and transplant immunology.
  • Transplant recipients deserve new treatment options with better efficacy and fewer side-effects to help protect their transplanted organs,” said Dr. Kirk.
  • Dr. Kirk has helped pioneer the use of co-stimulation pathway blockade to prevent organ rejection in transplant patients.

Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates

Retrieved on: 
Wednesday, September 6, 2023
Tacrolimus, Survival, American Society of Nephrology, Platelet, ASN, Congress, Incidence, Patient, Standard of care, Vivo, Risk, Organ transplantation, Primate, Immune system, Science Translational Medicine, Kidney, Kidney transplantation, Eledone, CD40L, Society, Safety, Pharmaceutical industry, Nephrology, FC

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the publication of a study evaluating tegoprubart as an immunomodulatory monotherapy in nonhuman primate kidney and islet allotransplants.

Key Points: 
  • IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the publication of a study evaluating tegoprubart as an immunomodulatory monotherapy in nonhuman primate kidney and islet allotransplants.
  • The study, entitled “The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates”, was published in the August 30, 2023, issue of Science Translational Medicine.
  • Results from the study showed that treatment with tegoprubart as a monotherapy promoted long-term kidney and islet allograft survival and function in nonhuman primates, indicating its potential as an immunomodulatory agent for organ transplantation.
  • Eledon expects to report updated clinical data from the Phase 1b study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023.

Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

Retrieved on: 
Wednesday, August 16, 2023
Exercise, Kidney transplantation, ASN, Eledone, American Society of Nephrology, Patient, Society, Pharmaceutical industry

IRVINE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the dosing of the 10th patient in the Company’s ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation and will report interim clinical data from this study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023.

Key Points: 
  • IRVINE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the dosing of the 10th patient in the Company’s ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation and will report interim clinical data from this study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023.
  • “We are pleased with the strong pace of enrollment in our Phase 1b trial and believe it speaks to the underlying demand for a new and better immunosuppressive regimen for the thousands of patients each year who undergo kidney transplantation,” said David-Alexandre C. Gros, M.D., Chief Executive Officer.
  • “This achievement represents the first successful clinical milestone in our recent financing agreement and positions us well to close the second tranche of funding upon the dosing of the 12th patient in our Phase 2 BESTOW study.
  • With the dosing of the 10th patient, the Company has now completed the first of two clinical development milestones related to the second tranche closing; the other clinical development milestone related to the second tranche closing is the dosing of the 12th patient in the Phase 2 BESTOW study that is expected to begin enrollment in the 3rd quarter of this year.

Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials

Retrieved on: 
Monday, May 1, 2023
Exercise, Capital market, Cantor, Exchange, Sale, Patient, Kidney transplantation, Security (finance), SVB Securities, Sanofi, Eledone

IRVINE, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage transplant and immunology-focused biopharmaceutical company, today announced that it has entered into a definitive securities purchase agreement with certain healthcare investors that will provide up to $185 million in gross proceeds to Eledon through a private placement. The purchase is comprised of an initial upfront financing of $35 million in exchange for 15.2 million common shares (or pre-funded warrants), representing a purchase price of $2.31 for each share of common stock and associated warrant sold at the initial closing, and up to an additional $105 million in mandatory tranche financing, subject to achieving specified milestones, including clinical development milestones. In addition, Eledon will have the potential to receive $45 million upon the full exercise of warrants being issued in connection with the agreement.

Key Points: 
  • In addition, Eledon will have the potential to receive $45 million upon the full exercise of warrants being issued in connection with the agreement.
  • The financing is being led by BVF Partners LP and Armistice Capital, and includes participation from new and existing investors including Sanofi (via Sanofi Ventures).
  • “This financing represents a significant commitment by our shareholders to advance the development of tegoprubart in kidney transplantation,” said David-Alexandre C. Gros, M.D., Chief Executive Officer.
  • Cantor, LifeSci Capital and Noble Capital Markets are acting as co-placement agents in connection with the financing.

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Retrieved on: 
Friday, March 31, 2023
Maintenance, Viremia, DNA, EGFR, Glomerular filtration rate, Biomarker, Transplant, Congress, Incidence, Patient, ATG, Kidney transplantation, United Kingdom, Eledone, Immunosuppression, BK, Safety, Biopsy, Pharmaceutical industry, Dietary supplement, Nephrology, IgA nephropathy

IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported results from the Company’s ongoing Phase 1b open-label trial evaluating tegoprubart in patients undergoing kidney transplantation at the World Congress of Nephrology, which is taking place March 30 to April 2, 2023. In addition, Eledon reported safety data from the Company’s Phase 2a trial of tegoprubart in IgA Nephropathy (IgAN).

Key Points: 
  • In addition, Eledon reported safety data from the Company’s Phase 2a trial of tegoprubart in IgA Nephropathy (IgAN).
  • The Phase 1b open-label study is enrolling up to 12 participants undergoing kidney transplantation in Canada, Australia, and the United Kingdom.
  • A second participant elected to discontinue the study after 33 weeks for reasons not attributed to tegoprubart or related to kidney function.
  • “We are highly encouraged by the results to date from our ongoing Phase 1b trial evaluating tegoprubart as a novel component of an immunosuppressive regimen in kidney transplant patients,” said David-Alexandre C. Gros, M.D., Chief Executive Officer.

eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies

Retrieved on: 
Monday, January 9, 2023
IND, Cell, CD154, Kidney, Heart, Manifest and latent functions and dysfunctions, Immunomodulation, Immunosuppression, FDA, Drug development, Immune system, Patient, CD40, Immunoglobulin G, CD40L, Pharmaceutical industry, Eledone

CAMBRIDGE, Mass. and IRVINE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that they have entered into a collaborative research agreement under which eGenesis will gain access to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ ongoing preclinical research and development studies of human-compatible organs and cells for the treatment of organ failure. The collaboration has the potential to span multiple eGenesis programs including kidney, heart and islet cell transplant.

Key Points: 
  • -Agreement leverages Eledon’s investigational anti-CD40L antibody, tegoprubart, as part of eGenesis’ immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients-
    -Establishes framework for use of tegoprubart for preclinical xenotransplantation studies in support of eGenesis’ kidney, heart and islet cell programs-
    CAMBRIDGE, Mass.
  • and IRVINE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that they have entered into a collaborative research agreement under which eGenesis will gain access to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ ongoing preclinical research and development studies of human-compatible organs and cells for the treatment of organ failure.
  • The collaboration has the potential to span multiple eGenesis programs including kidney, heart and islet cell transplant.
  • “Despite significant recent progress and momentum in the field of xenotransplantation, improving organ compatibility to prevent rejection remains an ongoing challenge,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results

Retrieved on: 
Monday, November 14, 2022
Autoimmune disease, CD154, United Kingdom, Kidney, Food, Cros, IND, Safety, Social media, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Cell Transplantation, Kidney transplantation, Research, Webcast, ID, ALS, CD40L, Coronavirus, Home After Three Months Away, FDA, Person, Pharmaceutical industry, Renewable energy, Eledone, IgA nephropathy

IRVINE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its third quarter 2022 operating and financial results and reviewed recent business highlights.

Key Points: 
  • Phase 1b trial evaluating tegoprubart for the prevention of rejection in patients receiving a kidney transplant
    IRVINE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (Eledon) (NASDAQ: ELDN) today reported its third quarter 2022 operating and financial results and reviewed recent business highlights.
  • Eledon plans to openU.S.sites under this IND as part of its ongoing global Phase 2a clinical trial evaluating tegoprubart for the treatment of IgAN.
  • Eledon will hold a conference call today,November 14, 2022,at4:30 pm Eastern Timeto discuss third quarter 2022 results.
  • Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter
    This press release contains forward-looking statements that involve substantial risks and uncertainties.

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Retrieved on: 
Thursday, November 3, 2022
CD40L, Eledone, CD154, ALS, Social media, Person, Autoimmune disease, Vaccine

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS.

Key Points: 
  • Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS.
  • The companys lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential.
  • Eledon is headquartered in Irvine, Calif. For more information, please visit the companys website at www.eledon.com .
  • Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter